Advances in the treatment of travelers' diarrhea

Current Gastroenterology Reports

Volumn 13, Issue 5, 2011, Pages 402-407

  Paredes Paredes, Mercedes ^a   Flores Figueroa, Jose ^a   DuPont, Herbert L ^a,b,c  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Enterotoxigenic E. coli; Travel medicine; Travelers' diarrhea

Indexed keywords

ACETORPHAN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZITHROMYCIN; BISMUTH SALICYLATE; CEFTRIAXONE; CIPROFLOXACIN; COTRIMOXAZOLE; CROFELEMER; DOXYCYCLINE; LEVOFLOXACIN; LOPERAMIDE; NALIDIXIC ACID; NORFLOXACIN; PLACEBO; PROBIOTIC AGENT; PRULIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMYCIN; RIFAXIMIN; ZALDARIDE MALEATE;

AFRICA SOUTH OF THE SAHARA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; BACTEROIDES FRAGILIS; BIFIDOBACTERIUM; BLASTOCYSTIS; CAMPYLOBACTER JEJUNI; CARIBBEAN ISLANDS; CRYPTOSPORIDIUM; DEVELOPING COUNTRY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; ENTAMOEBA HISTOLYTICA; ENTEROAGGREGATIVE ESCHERICHIA COLI; ENTEROTOXIGENIC ESCHERICHIA COLI; FECES CULTURE; FLUID THERAPY; GIARDIA; HEADACHE; HUMAN; INDUSTRIALIZATION; KLEBSIELLA OXYTOCA; LACTOBACILLUS; MEDICAL RESEARCH; MENTAL DISEASE; META ANALYSIS (TOPIC); MIDDLE EAST; MINIMUM INHIBITORY CONCENTRATION; NOROVIRUS; ORAL REHYDRATION THERAPY; PACIFIC ISLANDS; PHASE 3 CLINICAL TRIAL (TOPIC); QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SACCHAROMYCES; SALMONELLA; SELF MEDICATION; SHIGELLA; SINGLE DRUG DOSE; SOUTH AND CENTRAL AMERICA; SOUTH ASIA; SOUTHEAST ASIA; TRAVEL; TRAVELLER DIARRHEA;

ANTI-BACTERIAL AGENTS; ANTIDIARRHEALS; DIARRHEA; FLUID THERAPY; HUMANS; PROBIOTICS; TRAVEL;

EID: 80755125249     PISSN: 15228037     EISSN: 1534312X     Source Type: Journal    
DOI: 10.1007/s11894-011-0208-6     Document Type: Review

References (43)

1. Wang M, Szucs TD, Steffen R. Economic aspects of travelers' diarrhea. J Travel Med 2008; 15: 110-118. The authors estimated the economic burden of TD, the associated cost were estimated for pre-travel, during travel, and post travel phases. (Pubitemid 351393035)
2. World Tourism Organization. Tourism Highlights 2010 Edition. Available at: http://www.unwto.org/facts/menu.html). Accessed March 2011.
3. Greenwood Z, Black J, Weld L, et al. Gastrointestinal infection among international travelers globally. J Travel Med 2008; 15: 221-228. Authors performed a multicenter, retrospective observational analysis of 6086 travelers ill enough with gastrointestinal infection to seek medical care at a GeoSentinel clinic after completion of travel; reporting rate ratios were determined regional and countryspecific in comparison to risk in northern and western Europe. (Pubitemid 352020245)
4. Jiang ZD, DuPont HL, Brown EL, et al. Microbial etiology of travelers' diarrhea in Mexico, Guatemala, and India: importance of enterotoxigenic Bacteroides fragilis and Arcobacter species. J Clin Microbiol 2010; 48: 1417-1419. This study describes the presence of Acrobacter spp. and Enterotoxigenic Bacteroides fragilis associated with TD cases.
5. Flores J, DuPont HL, Jiang ZD, et al. Enterotoxigenic Escherichia coli heat-labile toxin seroconversion in US travelers to Mexico. J Travel Med. 2008;15:156-61. (Pubitemid 351724954)
6. Paredes-Paredes M, Okhuysen PC, Flores J, et al. Seasonality of Diarrheagenic Escherichia coli Pathotypes in the US Students Acquiring Diarrhea in Mexico. J Travel Med. 2011;18:121-5.
7. Meraz IM, Jiang ZD, Ericsson CD, et al. Enterotoxigenic Escherichia coli and diffusely adherent E. coli as likely causes of a proportion of pathogen-negative travelers' diarrhea-a PCRbased study. J Travel Med. 2008;15:412-8.
8. Shah N, DuPont HL, Ramsey DJ. Global etiology of travelers' diarrhea: systematic review from 1973 to the present. Am J Trop Med Hyg. 2009;80:609-14.
9. Villa NA, Okhuysen PC, Flores-Figueroa J, et al. Campylobacter jejuni is not an important pathogen as a cause of diarrhea in US travelers to Mexico. J Travel Med. 2011;18:56-8.
10. Koo HL, Ajami NJ, Jiang ZD, et al. Noroviruses as a cause of diarrhea in travelers to Guatemala, India, and Mexico. J Clin Microbiol. 2010;48:1673-6.
11. Torresi J, Leder K. Defining infections in international travellers through the GeoSentinel surveillance network. Nat Rev Microbiol. 2009;7:895-901.
12. Atia AN, Buchman AL. Oral rehydration solutions in non-cholera diarrhea: a review. Am J Gastroenterol. 2009;104:2596-604.
13. DuPont HL, Ericsson CD, Farthing MJ, et al. Expert review of the evidence base for self-therapy of travelers' diarrhea. J Travel Med 2009; 16: 161-171. The authors provide available evidence for the effectiveness of self-therapy of TD, recommendations are graded by the strength and quality of evidence.
14. Gallelli L, Colosimo M, Tolotta GA, et al. Prospective randomized double-blind trial of racecadotril compared with loperamide in elderly people with gastroenteritis living in nursing homes. Eur J Clin Pharmacol. 2010;66:137-44.
15. Bardhan PK, Sharma A, Bolmall C, et al. Safety and efficacy of a novel antisecretory anti-diarrheal agent Crofelemer (NP-303), in the treatment of adult acute infectious diarrhea and cholera, with or without the use of antibiotics (abstract). U.S.-Japan CMSP: 13th International Conference on Emerging Infectious Diseases (EID) in the Pacific Rim 2009, Kolkata India.
16. Ajami N, Koo H, Darkoh C, et al. Characterization of norovirusassociated traveler's diarrhea. Clin Infect Dis. 2010;51:123-30.
17. Norman FF, Pérez-Molina J, Pérez de Ayala A, et al. Clostridium difficile-associated diarrhea after antibiotic treatment for traveler's diarrhea. Clin Infect Dis. 2008;46:1060-3. (Pubitemid 351589872)
18. Fluoroquinolones: psychiatric adverse effects. Prescrire Int 2008; 17: 20.
19. Ouyang-Latimer J, Jafri S, Vantassel A, et al. In vitro antimicrobial susceptibility of bacterial enteropathogens isolated from international travelers to Mexico, Guatemala, and India from 2006 to 2008. Antimicrob Agents Chemother. 2011;55:874-8.
20. Mendez Arancibia E, Pitart C, Ruiz J, et al. Evolution of antimicrobial resistance in enteroaggregative Escherichia coli and enterotoxigenic Escherichia coli causing traveller's diarrhoea. J Antimicrob Chemother. 2009;64:343-7.
21. Serichantalergs O, Pootong P, Dalsgaard A, et al. PFGE, Lior serotype, and antimicrobial resistance patterns among Campylobacter jejuni isolated from travelers and US military personnel with acute diarrhea in Thailand, 1998-2003. Gut Pathog. 2010;2:15.
22. Vlieghe ER, Jacobs JA, Van Esbroeck M, et al. Trends of norfloxacin and erythromycin resistance of Campylobacter jejuni/Campylobacter coli isolates recovered from international travelers, 1994 to 2006. J Travel Med. 2008;15:419-25.
23. Pandey P, Bodhidatta L, Lewis M, et al. Travelers' diarrhea in Nepal: an update on the pathogens and antibiotic resistance. J Travel Med. 2011;18:102-8.
24. Fritsche TR, Biedenbach DJ, Jones RN. Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritisproducing pathogens, including those causing traveler's diarrhea. Antimicrob Agents Chemother. 2009;53:1221-4.
25. Giannarini G, Tascini C, Selli C. Prulifloxacin: clinical studies of a broad-spectrum quinolone agent. Future Microbiol. 2009;4:13-24.
26. DuPont HL, Jiang ZD, Walsh RB. A randomized, double-blind, placebo controlled phase III trial of prulifloxacin as therapy for traveler's diarrhea. In: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/46th Infectious Diseases Society of America (IDSA) Annual Meeting. Washington, DC: ASM Press 2008 [Abstract L-4134a].
27. Layer P, Andresen V. Review article: rifaximin, a minimally absorbed oral antibacterial, for the treatment of travellers' diarrhoea. Aliment Pharmacol Ther 2010; 31: 1155-1164. Authors included articles containing clinical data concerning the efficacy and safety of rifaximin in TD, 122 articles were identified and 10 were selected for analysis.
28. Hong KS, Kim YS, Han DS, et al. Efficacy of rifaximin compared with ciprofloxacin for the treatment of acute infectious diarrhea: a randomized controlled multicenter study. Gut Liver. 2010;4:357-62.
29. Study to Evaluate Safety and Efficacy of Rifamycin SVMMX for the Treatment of Traveler's Diarrhea Available at: www.ClinicalTrials. gov.Id:NCT01142089. Accessed March 2011.
30. Rifamycin SV-MMX® Tablets Versus Ciprofloxacin Capsules in Acute Traveller's Diarrhoea. Available at: www.ClinicalTrials.gov.Id:NCT01208922. Accessed March 2011.
31. Riddle MS, Arnold S, Tribble DR. Effect of adjunctive loperamide in combination with antibiotics on treatment outcomes in traveler's diarrhea: a systematic review and meta-analysis. Clin. Infect.Dis 2008; 47: 1007-1014. This meta-analysis evaluated 6 paired studies comparing antibiotics alone versus antibiotics in combination with loperamide.
32. Wine E, Gareau MG, Johnson-Henry K, Sherman PM. Strain-specific probiotic (Lactobacillus helveticus) inhibition of Campylobacter jejuni invasion of human intestinal epithelial cells. FEMS Microbiol Lett. 2009;300:146-52.
33. Lin PP, Hsieh YM, Tsai CC. Antagonistic activity of Lactobacillus acidophilus RY2 isolated from healthy infancy feces on the growth and adhesion characteristics of enteroaggregative Escherichia coli. Anaerobe. 2009;15:122-6.
34. Raheja G, Singh V, Ma K, et al. Lactobacillus acidophilus stimulates the expression of SLC26A3 via a transcriptional mechanism. Am J Physiol Gastrointest Liver Physiol. 2010;298: G395-401.
35. Bisson JF, Hidalgo S, Rozan P, Messaoudi M. Preventive effects of different probiotic formulations on travelers' diarrhea model in wistar rats: preventive effects of probiotics on TD. Dig Dis Sci 2010; 55: 911-919. This interesting paper shows, in addition to the effectiveness of a specific probiotic formulation, the use of a new animal model for TD.
36. A Comparison of Three Medications to Treat Diarrhea in Adults. Available at: www.ClinicalTrials.gov.Id:NCT00807326); Accessed March 2011.
37. Safety of Lactobacillus Reuteri (L. reuteri) in Healthy Adults. Available at: www.ClinicalTrials.gov.Id:NCT00922727; Accessed March 2011.
38. Safety of Lactobacillus reuteri in Healthy Volunteers Available at: www.ClinicalTrials.gov.Id:NCT00774163; Accessed March 2011.
39. Study to Evaluate the Safety of Lactobacillus rhamnosus GG ATCC 53103 (LGG) in Elderly Subjects. Available at: www. ClinicalTrials.gov.Id:NCT01274598; Accessed March 2011.
40. Safety of Lactobacillus rhamnosus GG ATCC 53103 (LGG) in Healthy Volunteers. Available at: www.ClinicalTrials.gov.Id:NCT00934453; Accessed March 2011.
41. Porter CK, Gormley R, Tribble DR, et al. The Incidence and gastrointestinal infectious risk of functional gastrointestinal disorders in a healthy US adult population. Am J Gastroenterol. 2011;106:130-8.
42. Haagsma JA, Siersema PD, De Wit NJ, Havelaar AH. Disease burden of post-infectious irritable bowel syndrome in The Netherlands. Epidemiol Infect. 2010;138:1650-6.
43. Paredes-Paredes M, DuPont HL, Garcia-Torres F, et al. 47th Infectious Diseases Society of America (IDSA) Annual Meeting. Vancouver Canada, 2010 [Abstract 123].